Syngene

News

EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy

The company anticipates submitting a biologics licence application for accelerated approval in the US in early 2026.

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close

Sections

Sections

Sections

Sections

Sections

EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy

Leading Strategic Intelligence Solutions for the Clinical Trials Industry

Key Lead Generation Providers and Technology Solutions for the Clinical Trials Industry

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

Sign up for our daily news round-up!

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Thank you for subscribing